BRCA1 and complete blood cell count: In contrast to FBC, BRCA2 mutations confer the greatest risk of MBC development compared to BRCA1 patients and the general population (BRCA2, 8% versus BRCA1, 2% versus wild type (WT), 0.1%) [45,47].